Biocon Limited.

NSE: BIOCON · Pharmaceuticals · sector

₹328.80NSE close 2026-10-26

Key numbers

Market cap₹53,581 cr

Price₹328.80

52w high / low₹447 / ₹329

P/E96.7xSector median 27.9x

P/B1.6xSector median 2.9x

Book value₹208.8

Dividend yield0.17%Sector median 0.48%

ROE1.8%Sector median 11.7%

ROCE2.9%Sector median 12.3%

OPM18.1%Sector median 14.0%

Debt / equity0.44xSector median 0.16x

EV/EBITDA20.6xSector median 18.6x

Interest cover1.5x

Current ratio1.22x

Sales growth 3y+14.8%Sector median +9.6%

Profit growth 3y-5.9%Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹3,883 cr vs borrowings ₹14,825 cr (FY26): borrowings are higher by ₹10,941 cr.
Operating profit covered interest 1.5x in the last 12 months.
No promoter shares are pledged.
Promoter holding fell by 9.77 percentage points in a year, to 44.68% (2026-09-30).
Operating cash flow was below net profit in 0 of the last 5 years.
Net loss in 1 of the last 8 quarters.
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 64% of net profit in the last 12 months.
Debtor days went from 154 (FY24) to 129 (FY26).
Dividend paid in 4 of the last 5 financial years.
Price ₹328.80 on 2026-10-26: -26.5% from the 52-week high, 0.0% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹437.95 · low ₹305.05

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	3,590	3,821	4,417	3,942	4,296	4,173	4,517	4,336
EBITDA	711	770	1,099	749	824	540	940	834
OPM %	19.8%	20.1%	24.9%	19.0%	19.2%	12.9%	20.8%	19.2%
Other income	32	35	37	80	93	117	52	54
Net profit	-16	25	344	31	84	144	126	141
EPS (₹)	-0.13	0.21	2.88	0.26	0.66	1.08	0.79	0.87
Revenue YoY					+19.6%	+9.2%	+2.3%	+10.0%
Profit YoY					–	+472.9%	-63.5%	+349.4%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	8,184	11,174	14,756	15,262	16,927	17,321
EBITDA	1,859	2,220	3,287	3,263	3,052	3,137
Net profit	648	463	1,022	1,013	386	495
EPS (₹)	5.44	3.88	8.55	8.46	2.82	3.40
Revenue growth		+36.5%	+32.1%	+3.4%	+10.9%	+9.8%
Profit growth		-28.6%	+121.0%	-0.9%	-61.9%	+28.6%
Dividend / share (₹)	–	0.50	1.50	0.50	0.50

Compounded growth	3 years	5 years	Last 12 months
Sales	+14.8%	+19.0%	+9.8%
Net profit	-5.9%	-12.2%	+28.6%
EPS	-10.1%	-14.7%	–
Share price	–	-0.4% (2y)	-8.5%

Balance sheet

₹ cr	FY22	FY23	FY24	FY25	FY26
Shareholders' equity	–	17,867	19,784	21,644	34,032
Borrowings	–	17,771	15,730	17,756	14,825
Cash & equivalents	–	3,727	2,574	4,568	3,883
Total assets	–	52,043	56,071	58,797	63,651
Fixed assets	–	7,535	7,418	8,708	9,473
Capital work in progress	–	2,588	3,985	4,102	4,613
Investments	–	604	684	680	1,089
Receivables	–	3,573	6,231	5,488	5,987
Inventory	–	4,244	4,944	4,931	6,086
Payables	–	3,983	6,272	6,549	6,772

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,177	1,852	2,954	4,061	1,994
Cash from investing	-1,699	-14,282	-1,004	-234	-2,082
Cash from financing	242	13,049	-2,333	-1,854	-924
Capex	1,925	1,726	1,932	2,343	1,912
Free cash flow	-748	126	1,022	1,718	82

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY22	FY23	FY24	FY25	FY26
ROE %	–	2.6%	5.2%	4.7%	1.1%
ROCE %	–	4.2%	7.3%	7.1%	2.9%
Debtor days	–	117	154	131	129
Inventory days	–	423	368	346	390
Payable days	–	397	467	460	434
Cash conversion cycle (days)	–	143	55	17	85
Working capital days	–	125	-4	47	67

Shareholding

Holder	% (2026-09-30)
Promoters	44.68%
FIIs	8.64%
DIIs	29.30%
of which Mutual funds	22.08%
of which Insurance	5.55%
Public (non-institutions)	17.20%

Quarter	Sep 2025	Dec 2025	Jan 2026	Jan 2026	Mar 2026	Jun 2026	Jun 2026	Sep 2026
Promoters %	54.45%	54.45%	48.27%	44.91%	44.91%	44.68%	44.68%	44.68%

Promoter group	%
Kiran Mazumdar-shaw	29.73%
Glentec International	14.56%
Ravi Rasendra Mazumdar	0.33%
DEV Mazumdar	0.06%
Glenloch Properties LLP	0.00%
Mazumdar Shaw Medical Foundation	0.00%
Carica Investments	0.00%
Jeeves	0.00%

Public holders above 1%	%
SBI ESG Exclusionary Strategy Fund	9.18%
ICICI Prudential Retirement Fund-pure Equity Plan	4.07%
Serum Institute Life Sciences Private Limited	3.40%
Lici NEW Pension Plus Growth Fund	2.62%
Kotak Large & Midcap Fund	2.57%
HDFC Mutual Fund - HDFC Dividend Yield Fund	1.07%

3,93,051 shareholders. Pledged: 0.00% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
BIOCON	₹53,581 cr	96.7x	1.6x	1.8%	2.9%	18.1%	+14.8%	0.17%

All 185 companies in Pharmaceuticals →

Business segments (FY26)

Segment	Revenue	Share	EBIT	Margin
Biosimilars	₹10,431 cr	60.2%	₹588 cr	5.6%
CRDMO	₹3,739 cr	21.6%	₹488 cr	13.0%
Generics	₹3,168 cr	18.3%	₹-135 cr	-4.3%

Dividends & corporate actions

Ex-date	Action	Detail
2026-07-03	Dividend	Dividend - Re 0.50 Per Share
2025-07-04	Dividend	Dividend - Rs 0.50 Per Share
2024-07-05	Dividend	Dividend - Re 0.50 Per Share
2023-07-07	Dividend	Dividend - Rs 1.50 Per Share
2022-06-30	Dividend	Dividend - Rs 0.50 Per Share
2019-07-18	Dividend	Dividend - Rs 0.50 Per Share
2019-06-12	Bonus	Bonus 1:1
2018-07-19	Dividend	Dividend- Re 1 Per Share
2017-07-20	Dividend	Annual General Meeting/Dividend - Re 1/- Per Share
2017-06-15	Bonus	Bonus 2:1
2016-06-22	Other	Annual General Meeting
2016-03-17	Dividend	Interim Dividend - Rs 5/- Per Share (Purpose Revised)
2015-07-16	Other	Annual General Meeting
2015-04-09	Dividend	Interim Dividend Rs 5/- Per Share
2014-07-10	Dividend	Annual General Meeting / Final Dividend - Rs 5/- Per Share
2013-07-11	Dividend	Annual General Meeting/Final Dividend Rs 5/- Per Share + Special Dividend Rs 2.5/- Per Share
2012-07-05	Dividend	Annual General Meeting / Dividend Rs 5 Per Share
2011-07-07	Dividend	Annual General Meeting/Dividend Rs 3 Per Share
2011-05-05	Dividend	Interim Dividend-Rs.1.50 Per Share (Purpose Revised)
2010-07-08	Dividend	Annual General Meeting And Dividend Rs.3.50 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Generics:
Biosimilars: As a global leader in biosimilars, Biocon Biologics has a strong track record across the value chain, from R&D to manufacturing and commercialization. It is among the few global players with a comprehensive biosimilars portfolio, addressing key therapeutic areas such as oncology, diabetes, and immunology. With a continued focus on quality, affordability, and access, Biocon Biologics is working towards advancing health equity worldwide.
CRDMO*: Provide scientific solutions through integrated research, development, and manufacturing


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	BIOCON
BSE code	532523
ISIN	INE376G01013
Face value	₹5.0
Incorporated	1978-11-29
Website	www.biocon.com
Plants (India / abroad)	5 / 1

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.